PT-141

Name: PT-141
Brand: Limitless Peptides
SKU: PT141-10-601
Price: 80.00 USD
Availability: InStock

Purity: 99.727%

Batch #: PT141-10-601

Verified Potency: 10.66mg

$80.00

PT-141 (Bremelanotide) is a synthetic peptide investigated for its interaction with melanocortin receptors and central nervous system pathways related to arousal and neuroendocrine signaling.

Size

3rd-Party Janoshik Verification

Ships by Calculating...

Disclaimer

For Research Use Only. Not for human consumption or therapeutic treatment.

About PT-141

PT-141, also known as Bremelanotide, is a cyclic peptide analog that selectively targets melanocortin receptors, particularly MC3R and MC4R, in the central nervous system. Unlike approaches that focus on vascular mechanisms, PT-141 works through hypothalamic signaling pathways, making it a unique tool for studying neural regulation of physiological arousal and behavioral responses. Research explores its influence on neuroendocrine communication, melanocortin system function, and CNS-mediated pathways. Scientists value PT-141 for its distinctive mechanism of action and its ability to provide insights into how the brain orchestrates complex physiological and behavioral patterns through peptide signaling.

Product Specifications

PT-141 Lyophilized Powder in 3ml vial

Application

Melanocortin receptor and neuroendocrine pathway research

Appearance

Solid, white powder in 3mL glass ampule

Chemical Formula

C50H68N14O10

CAS number

189691-06-3

Molecular Weight

~1025.2 g/mol

FAQs

What is PT-141?

PT-141, also known as bremelanotide, is a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It is a synthetic analog of alpha-melanocyte-stimulating hormone that was developed from the metabolite of melanotan II. PT-141 received FDA approval in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women, making it the first melanocortin receptor agonist approved for this indication.

What receptor does PT-141 activate?

PT-141 is an agonist of the melanocortin-4 receptor, which is expressed in the hypothalamus and other brain regions involved in sexual arousal and appetitive behavior. MC4R activation by PT-141 initiates downstream signaling through the cyclic AMP and phospholipase C pathways. Unlike phosphodiesterase inhibitors used in erectile dysfunction, PT-141 acts centrally through the nervous system rather than peripherally on vascular smooth muscle.

How does PT-141 differ from melanotan II?

PT-141 was derived from melanotan II but differs in that it is a cyclic peptide without the linear extension that gives melanotan II its melanogenic (skin-darkening) effects. PT-141 retains melanocortin-4 receptor selectivity while having reduced activity at melanocortin-1 receptor, which mediates pigmentation. This structural modification reduces tanning effects while preserving the central nervous system activity associated with sexual function research.

What clinical data exists for PT-141?

FDA approval of bremelanotide was based on two Phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT studies) involving over 1,200 premenopausal women with hypoactive sexual desire disorder. Treatment with 1.75 mg subcutaneous bremelanotide resulted in statistically greater increases in desire and reduction of distress compared to placebo. Common reported adverse effects included nausea, flushing, and headache. The drug carries a boxed warning regarding transient increases in blood pressure.

Can I buy PT-141 for research?

Limitless Peptides sells PT-141 as a lyophilized powder in a sealed 3mL glass ampule. The product is Janoshik verified for identity, potency, and purity. PT-141 is sold for research use only. The product page includes the manufacturer's certificate of analysis and a link to the independent Janoshik verification report.

PT-141

About PT-141

FAQs

Related Peptides